LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

Area of Science:

• Respiratory Medicine
• Pharmacology
• Clinical Trials

Background:

• Chronic Obstructive Pulmonary Disease (COPD) management often involves bronchodilators.
• Long-acting beta-agonists (LABA) and long-acting muscarinic antagonists (LAMA) are key components in COPD therapy.
• Fixed-dose combinations (FDCs) aim to simplify treatment regimens.

Purpose of the Study:

• To systematically review the evidence for LABA/LAMA FDCs in COPD treatment.
• To compare the efficacy of LABA/LAMA FDCs against other bronchodilator therapies.
• To assess safety and specific outcome improvements with LABA/LAMA FDCs.

Main Methods:

• Systematic literature search of randomized controlled trials up to September 2017.
• Included studies compared LABA/LAMA FDCs with LABA, LAMA, or LABA/inhaled corticosteroid (ICS) FDCs.
• Evaluated outcomes included lung function (FEV1), dyspnea, quality of life, exacerbations, exercise tolerance, and rescue medication use.

Main Results:

• LABA/LAMA FDCs significantly improved lung function (FEV1) compared to LABA, LAMA, or LABA/ICS, with sustained effects.
• Improvements were noted in Transition Dyspnea Index (TDI) and St George's Respiratory Questionnaire (SGRQ) scores, though heterogeneity exists.
• Indacaterol/glycopyrronium demonstrated superiority in reducing exacerbations and improving exercise tolerance and inspiratory capacity compared to certain comparators. Rescue medication use was reduced.

Conclusions:

• Evidence for LABA/LAMA FDCs in COPD is robust, with significant improvements in lung function and patient-reported outcomes.
• Indacaterol/glycopyrronium exhibits the strongest evidence for superiority across various efficacy endpoints.
• LABA/LAMA FDCs are generally safe, but real-world data are needed to further confirm long-term safety profiles.